Close Menu

NEW YORK (GenomeWeb) — Ag-bio startup Amfora announced today that it has acquired a nonexclusive license to intellectual property covering CRISPR-Cas9 genome editing and related technologies from DowDuPont's Corteva Agriscience and the Broad Institute.

San Francisco-based Amfora, which closed a $5 million Series A round roughly two years ago, aims to develop nutritionally enhanced food and feed crops. Under the terms of the license, Amfora will be able to use the IP to develop crops with increased protein content.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.